Sales & Marketing News | pharmaphorum

News

Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.

News

Trump has threatened to impose across-the-board tariffs of 25% on pharma imports, which analysts warn could drive up costs for industry and patients.

News

Around 1,400 patients with Lennox-Gastaut Syndrome will be eligible for NHS treatment with UCB's Fintepla after a NICE recommendation.

News

Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.

News

Shionogi will market the EndeavorRide app, originally licensed from Akili, in Japan following its approval by the MHLW regulator.

News

The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.